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A
fter decades of relative quies-
cence, G protein coupled
receptor theory (GPCR) is un-
dergoing a conceptual revolu-
tion driven in large part by findings like
those of Schmid et al. as reported in this
issue of PNAS (1). Since 1966, hypothe-
ses of drug action at GPCRs have been
driven by the quaint notion of ‘‘intrinsic
efficacy’’ (2), which proposes that drugs
which completely activate GPCRs (e.g.,
full agonists) remain full agonists re-
gardless of the cellular milieu (see ref. 3
for a recent review). In other words, to
paraphrase Gertrude Stein, ‘‘an agonist
is an agonist is an agonist.’’ Over the
past several years, based mainly on in
vitro findings with synthetic agonists, it
has become evident that the notion of
‘‘intrinsic efficacy’’ is a myth and that
the cellular milieu is a critical determi-
nant of drug action. As Schmid et al.
elegantly demonstrate, the actions in
vivo of the naturally occurring agonist
serotonin (5-hydroxytryptamine; 5-HT)
are profoundly altered by the comple-
ment of arrestins expressed in neurons
(1). These findings will force neurophar-
macologists to fundamentally alter their
notions of drug actions at neuronal re-
ceptors and will have a major impact on
central nervous system (CNS) drug dis-
covery efforts.
For many years it has been clear that
the hallucinogens lysergic acid diethyl-
amide (LSD), psilocybin, and mescaline
exert their actions in vivo principally via
5-HT2A serotonin receptor activation
(4). According to classical concepts of
receptor pharmacology, one would pre-
dict any drug that activates 5-HT2A sero-
tonin receptors will be hallucinogenic. It
has also been widely appreciated for
decades, however, that several small
molecules, including the endogenous
agonist 5-HT, can activate 5-HT2A re-
ceptors but do not induce hallucinations.
Thus, for instance, the LSD analogue
lisuride, which is prescribed in Europe
for the treatment of Parkinson’s disease,
is a potent 5-HT2A agonist devoid of
appreciable hallucinogenic actions in
vivo (4, 5). Additionally, several groups
have demonstrated that various 5-HT2A
agonists cause differential patterns of
signal transduction in vitro and in vivo
(5–7). Invariably, when a large number
of 5-HT2A receptor agonists are exam-
ined, discrete patterns of signal trans-
duction are seen. Thus, for instance, the
hallucinogenic agonists 2,5-dimethoxy-4-
iodoamphetamine (DOI) and LSD and
the nonhallucinogenic agonists lisuride
and 5-HT all evoke distinctive patterns
of activation of phospholipase C, arachi-
donic acid release, and transcription fac-
tor expression in cells expressing 5-HT2A
receptors (5–7).
A number of researchers have at-
tempted to modify the framework
underlying receptor theory to accommo-
date the aforementioned phenomena,
and many of the ideas generated fall
under the rubric of ‘‘functional selectiv-
ity,’’ ‘‘biased agonism,’’ ‘‘agonist di-
rected trafficking of receptor stimulus,’’
and so on (8). In this review, we will use
the term functional selectivity (3). There
are three key types of observations
which support the concept of functional
selectivity. First, it is clear that there are
multiple active states for GPCRs and
that receptor populations exist in what
are essentially conformational assem-
blages (8). Second, different ligands
either induce or stabilize different en-
sembles of active conformations (3).
Similarly, networks of GPCR-interacting
proteins, including arrestins, G proteins,
and caveolins (to name just a few), form
unique local environments, leading to
differential patterns of agonist respon-
siveness (9, 10). Third, these different
active states lead to the different signal-
ing pathways downstream of a single
GPCR. Thus, ligands can selectively ac-
tivate a subset of downstream signaling
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Fig. 1. Functional selectivity at the 5-HT2A receptor is mediated by -arrestin. The absence of -arrestin2
abrogrates many 5-HT induced downstream events at 5-HT2A receptors, including internalization, head
twitch, and p-ERK, but has little to no effect on those same signaling pathways when DOI is the ligand in
question.











pathways by inducing or stabilizing the
appropriate active states.
Schmid et al. present a compelling set
of observations that can only be expli-
cated by the emerging concept of func-
tional selectivity (1). The authors begin
by examining the head twitch response,
a 5-HT2A receptor activation-mediated
behavior characteristic of hallucinogens
(11), in wild-type and -arrestin2 knock-
out mice. The use of -arrestin2 knock-
out mice was fortuitous because of an
emerging body of data indicating that
GPCRs use arrestins for promoting an
‘‘arrestinergic’’ pattern of signaling (re-
viewed in ref. 9). Schmid et al. find that
injections of the 5-HT precursor
5-hydroxytryptophan (5-HTP) induce a
robust head-twitch response in wild-
type, but not in -arrestin2 knockout,
mice. Amazingly, the synthetic halluci-
nogen DOI elicits the same robust re-
sponse in wild-type and -arrestin2
knockout mice. The authors also dem-
onstrate that deleting -arrestin2 does
not alter 5-HT2A receptor levels and
that both responses are blocked by a
selective 5-HT2A antagonist. These find-
ings indicate that the in vivo responses
to the agonists 5-HT and DOI at a sin-
gle GPCR are differentially altered by
the presence of -arrestin2 scaffold.
Schmid et al. then perform an elegant
series of in vitro and in vivo biochemical
and cell biological studies to elucidate
the potential mechanisms responsible
for this differential responsiveness. The
authors show, for example, a differential
pattern of -arrestin sensitivity for ago-
nist-mediated internalization and ERK
phosphorylation in murine embryonic
fibroblasts and cortical pyramidal cells
in culture (see Fig. 1). In agreement
with prior studies, they demonstrate that
the -arrestin sensitivity is critically de-
pendent upon the cellular milieu (12).
They also demonstrate that the differen-
tial arrestin-requirement recapitulates, in
some but not all instances, the differen-
tial arrestin requirement for in vivo be-
havioral responses.
Altogether, the findings of Schmid et
al. cannot be reconciled with classical
pharmacology theory. For example, the
initial finding that 5-HTP-induced head
twitch is dramatically reduced in
-arrestin2 knockout mice leads to the
prediction that DOI’s effects must be
similarly diminished. Instead, deleting
-arrestin2 differentially alters the re-
sponse to 5-HTP and DOI. The same
holds true for the distinctively differen-
tial effects of arrestin depletion on
signaling induced by DOI and 5-HT.
However, if one considers the possibility
that 5-HT and DOI induce (or stabilize)
discrete ensembles of active conforma-
tions, the above data can be readily ex-
plained by functional selectivity (see Fig.
1). Indeed, the findings by Schmid et al.
suggest that the absence of -arrestin
has a far more dramatic effect in terms
of changing the conformational ensem-
bles that can be induced or stabilized by
5-HT as compared with DOI. Lefkowitz
and colleagues (9, 17, 18) have also sug-
gested that arrestins may differentially
modulate the actions of GPCR agonists.
The studies by Schmid et al., as well
as others (13), also have implications for
therapeutic drug discovery. Given that
ligands apparently induce differential
patterns of signal transduction, it should
be possible to design drugs that stabilize
these unique conformational ensembles.
This theoretical framework may be help-
ful in designing useful drugs by helping
to determine what sort of stimulus path-
way activation profile is most therapeu-
tic, and, conversely, which pathways
might be responsible for undesirable
side effects. Indeed, we and others have
suggested that novel atypical antipsy-
chotic drugs that activate D2-dopamine
receptors (e.g., aripiprazole, bifeprunox,
preclamol) are beneficial precisely be-
cause of their functional selectivity (14,
15). One can envision a scenario
whereby drugs are identified via differ-
ential actions at a panel of functional
readouts, yielding compounds with en-
hanced therapeutic efficacy and fewer
side effects (16). Given the multiplicity
of signaling events that can be elicited
by a single GPCR, it is likely that re-
searchers in academia and the pharma-
ceutical industry will be exploiting the
predictions that result from the func-
tional selectivity hypothesis for years to
come.
1. Schmid CL, Raehal KM, Bohn LM (2008) Proc Natl Acad
Sci USA 105:1079–1084.
2. Furchgott RF (1966) in Advances in Drug Research, eds
Harper N, Simmonds A (Academic, New York), Vol 3, pp
21–55.
3. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka
B, Weinstein H, Javitch JA, Roth BL, Christopoulos A,
Sexton PM, et al. (2007) J Pharmacol Exp Ther 320:1–13.
4. Nichols DE (2004) Pharmacol Ther 101:131–181.
5. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic
L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, et al.
(2007) Neuron 53:439–452.
6. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P,
Clarke WP (1998) Mol Pharmacol 54:94–104.
7. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE
(2003) J Pharmacol Exp Ther 304:229–237.
8. Kenakin T (2002) Nat Rev Drug Discov 1:103–
110.
9. Violin JD, Lefkowitz RJ (2007) Trends Pharmacol Sci
28:416–422.
10. Yan F, Mosier PD, Westkaemper RB, Roth BL (2008)
Biochemistry, in press.
11. Glennon RA, Titler M, McKenney JD (1984) Life Sci
35:2505–2511.
12. Gray JA, Sheffler DJ, Bhatnagar A, Woods JA,
Hufeisen SJ, Benovic JL, Roth BL (2001) Mol Pharma-
col 60:1020 –1030.
13. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT,
Ahn S, Shenoy SK, Lefkowitz RJ (2007) Proc Natl Acad
Sci USA 104:16657–16662.
14. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX,
Sibley DR, Roth BL, Mailman R (2003) Neuropsychop-
harmacology 28:1400–1411.
15. Urban JD, Vargas GA, von Zastrow M, Mailman RB
(2007) Neuropsychopharmacology 32:67–77.
16. Mailman RB (2007) Trends Pharmacol Sci 28:390–396.
17. Lefkowitz RJ, Rajagopal K, Whalen J (2006) Mol Cell
24:643–652.
18. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007)
Annu Rev Physiol 69:483–510.
It has become evident
that the notion of
‘‘intrinsic efficacy’’
is a myth.
832  www.pnas.orgcgidoi10.1073pnas.0711335105 Abbas and Roth
